🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Healthcare professionals: Check out Poster # 901 at the American Society of Nephrology Kidney Week on Oct. 24 at 10:00 AM PT for an analysis of cardiovascular safety of an oral HIF-PHI in a Phase 3 program: asn-online.org/education/kidn…

At American Society of Nephrology Kidney Week 2024? Stop by to see Team Akebia at Booth #2202 in the Exhibit Hall. We're eager to connect with the Nephrology Community!

ASN attendees: Visit the poster gallery today at 10:00 AM PT to view Poster #902 for safety data on an oral HIF-PHI: asn-online.org/education/kidn…

Healthcare professionals American Society of Nephrology #KidneyWk: We're sharing the framework for assessing the risk-benefit of treatments and dosing regimens for CKD anemia. Poster # 900 is available now in the poster gallery: asn-online.org/education/kidn…

It’s been a great start to American Society of Nephrology #KidneyWk! Akebia Therapeutics experts are at Booth #2202 and discussing our latest research in chronic kidney disease. Be sure to visit Akebia Medical Affairs at Booth #2202!

Akebia in Action at ASN Kidney Week. Stop by Booth #2202 to meet the team.

Thank you to the American Society of Nephrology for a meaningful and productive #KidneyWk 2024. We are leaving San Diego energized and confident that together we can better the lives of people impacted by kidney disease.

PRESS RELEASE: Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights. Link: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights. Link: ir.akebia.com/news-releases/…

PRESS RELASE: Akebia Therapeutics to Present at the Jefferies London Healthcare Conference. Link: ir.akebia.com/news-releases/… #JefferiesHealthcare

Exciting news! The AJKD has published important findings from Akebia's FOCUS trial on an oral HIF-PH inhibitor. PRESS RELEASE: shorturl.at/bAlid

Akebia is looking forward to participating in the Piper Sandler 36th Annual Virtual Healthcare Conference on December 3, 2024. #PSCHealthcare2024 - Click link for more information: ir.akebia.com/news-releases/…

We’re proud to announce that our oral HIF-PH inhibitor is now shipping in the U.S. Click to read the release: ir.akebia.com/news-releases/….

PRESS RELEASE: Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results. Click for link to release: ir.akebia.com/news-releases/…

PRESS RELEASE: Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025: ir.akebia.com/news-releases/…

We're getting ready for National Kidney Foundation Spring Clinical Meetings 2025 in our own backyard in Boston! We’re eager to connect with the kidney community, review research and discuss the latest treatments for patients. Attending? Visit Akebia at Booth #1121 in the Exhibit Hall.

SCM25 #NKFClinicals is less than a week away! Check out the Akebia Medical Affairs Exhibitor Showcase at Booth 1221 on Friday, April 11 at 7:30 am to learn about hypoxia-inducible factor activation in anemia due to CKD and our latest clinical research. We hope to see you there!

PRESS RELEASE: Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights. Link: ir.akebia.com/news-releases/…

PRESS RELEASE - Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference: ir.akebia.com/news-releases/…